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nized by C. albicans, C. slabrata appears to emerge 
as the second most prevalent species. 
Supported by NIH/NIDCR DE016466 and MO1 RR06192. 
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Goal: To validate oral vatgancictovir (VGC) in the 
prophylaxis of CMV infection in Lung (Lu) and 
Liver (L) recipients and in the treatment of CMV 
infection/disease in solid organ transplant recipi- 
ents, using pharmacokinetic and pharmacodynamic 
studies in comparison with i/v gancicLovir (GCV). 
Methods: patients undergoing organ transpLanta- 
tion donor or recipient CMV-seropositive receiv- 
ing VGC prophylaxis for a period of 3 months 
(D+/R- Lung recipients, 6 months) were enroLLed. 
Heart (H), Lu, and L recipients received 900mg 
VGC q.d., adjusted to kidney (K) function. No K re- 
cipients received more than 450mg of VGC q.d. 
GCV trough (Ctrough) and peak (Cpeak = 3 hours af- 
ter drug administration) LeveLs, and CMV DNA were 
measured at 7, 30, and 60 days post-transpLant 
(prophyLactic study). Patients who developed CMV 
infection/disease after stopping prophylaxis were 
treated with VGC (1800mg per day adjusted to 
K function and GCV blood LeveLs). GCV trough and 
peak LeveLs, and CMV DNA were measured weekly 
for the first 3 weeks and biweekly thereafter, until 
therapy cessation (therapeutic study). PLasma con- 
centration of GCV is measured by HPLC. 
Results: In the first 8 prophyLaxed patients (6 K, 
and 1 L and 1 H transplant recipient) of 450mg 
VGC q.d., the average GCV concentration was 
0.5±0.3 mg/t at trough, and 3.9±l.0mg/t 3 hours 
after administration. Inter-patient variability was 
substantiaL, especiaLLy for Ctrough (63% of total 
variance), which correlated with the patient's esti- 
mated gtomerutar filtration rate (r square = 42%). 
No CMV DNA was detected during VGC prophy- 
Laxis. Two patients (1 H and 1 L) were treated 
for Late CMV disease. Average GCV Cpeak were 
8.9±2.3 mg/L and 4.6±0.5 rag/L, and GCV Ctrough 
were 2.0±0.9 mg/t and 1.6±0.2 mg/t respectively 
in each patient during induction phase. VGC treat- 
ment afforded a decrease in CMV DNA from 5.2 
and 4.4 Log copies/10E6 cettutes at week 0, to 3.9 
and 3.0 at week 1, and 3.3 and 2.1 at week 3, 
respectively. 
Conclusion: by demonstrating that vatgancictovir 
produces drug LeveLs and viral responses similar 
to i/v gancictovir, this approach is promising as a 
cost effective alternative to randomized controLLed 
studies in validating an oral prodrug in new indica- 
tions. 
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Background: The optimal strategy for prevention 
of CMV disease foLLowing renal transplantation is 
a matter of debate. ProphyLactic treatment may 
result in Late CMV disease, whereas preemptive 
treatment warrants regular consultations with Lab- 
oratory screening. At our center, a preemptive 
strategy is used for high-risk (D+/R-) while foLLow- 
up for intermediate (R+) or Low risk (D-/R-) patients 
is based on cLinicaL symptoms. 
Objectives: The aim of this retrospective analysis 
was to study the occurrence of CMV-antigenemia, 
-viral syndrome and -organ disease in renal trans- 
plant recipients and to correlate their respective 
impact on graft function and Length of hospitaLiza- 
tion, respectively. 
Methods: ALL patients receiving a renal transplant 
from 1/1998 to 12/2003 with a completed foLLow- 
up of 2 years were included. High risk patients 
(D+/R-, group 1) had pp65 surveiLLance tests at 
regular intervals. Antivirat therapy was initiated if 
antigenemia was detected. The outcome of high- 
risk patients was compared with intermediate-risk 
(R+, group 2), and Low-risk (D-/R-, group 3) pa- 
tients. 
Results: A total of 363 patients were eLigibLe, 
69 (19%) were D+/R- (group 1), 230 (63%) were 
D+/R+ or D-/R+ (group 2) and 64 (18%) were D-/R- 
(group 3). The preemptive treatment strategy was 
used in 59 (84%) patients of group 1, 9 (4%) of 
group 2 and 2 (3%) of group 3. ProphyLaxis with gan- 
cictovir (?) was used in 6 (9%) patients of group 1, 
aLL remaining patients were foLLowed cLinicaLLy. 
OveraLL, 70 (20%) patients suffered from at Least 
one CMV episode (antigenemia, viral syndrome, or 
end organ disease). In group 1, 43 (62%) patients 
experienced a CMV episode, 8 (19%) had viremia, 
